



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Ref.: ADL/SE/2017-18
Date: 21st August, 2017

To,
Department of Corporate Service,
BSE Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001.
BSE CODE - 524348

To,
National Stock Exchange of India Limited,
"Exchange Plaza", Bandra - Kurla Complex,
Bandra (E), Mumbai - 400051.
NSE SYMBOL: AARTIDRUGS

Sub: Press Release

Dear Sir/Madam,

Please find enclosed herewith copy of the press release issued by the Company on 21st August, 2017.

This is for your kind information and records. Kindly acknowledge the receipt.

Thanking you,

Yours faithfully,
For Aarti Drugs Limited

Vibhav S. Ranade
Company Secretary & Compliance Officer



Encl: A/A



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel. : 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Press release for Jun'17

GST transition affected the domestic sales heavily in June quarter leading to decline in local sales to the extent of approximately 18%. However, there was good demand growth in export markets recording the volume growth of around 20.5% and the value growth of around 5.5% due to lower foreign exchange rate.

Consolidated Profit after tax for the quarter ended Jun'17 is 11.38 crores and Consolidated EBITDA for the quarter ended Jun'17 is 35.46 crores. Despite of the lower profit due to GST transition impact, Debt/Equity ratio was maintained at 1.13 as of Jun'17. Lower domestic sales affected the absolute gross contribution due to which operating margins were affected temporarily in this quarter.

Company is confident to face USFDA audit in recent future. Approvals for three of its products for European markets and marketing authorization of Zolpidem and Celecoxib tablets in UK and Ireland will positively impact the exports in future. Company has just commissioned centralized multiple effect evaporator systems to reduce the effluent streams, thus positively contributing towards the cleaner environment.

For Aarti Drugs Limited

Harshit M. Savla
Jt. Managing Director

